#	Pagina
attuale pagina	/open-h2020/projects/194714/index.html
-1	/open-h2020/per-topic/nanolayers/list/index.html
-2	/open-h2020/per-topic/muddy/list/index.html
-3	/open-h2020/projects/214348/deliverables.html
-4	/open-h2020/per-topic/vigilance/list/index.html
-5	/open-h2020/per-topic/denitrification/list/index.html
-6	/open-h2020/per-topic/wallboard/list/index.html
-7	/open-h2020/per-topic/reviving/list/index.html
-8	/open-h2020/per-topic/q4/list/index.html
-9	/open-h2020/per-coordinator/be/eit+digital/index.html
-10	/open-h2020/per-topic/unselected/list/index.html

Opendata, web and dolomites

TISSUE

Tissue In Stroke Stratification Using e-ASPECTSTW

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TISSUE project word cloud

Explore the words cloud of the TISSUE project. It provides you a very rough idea of what is the project "TISSUE" about.

patients size benefits intravenous device eligible aspectstw participating socioeconomic restricted acute 275 stratification full time economic position thrombolysis prospective pricing neurological centre plan symptom arrive trial units competition output nccts 250 medical tomography onset additional global leaders treatment clinically burden accessible feasibility imaging benefit indirect hospitals ncct worldwide approved commercial standardised contrast tissue business profits cerebrovascular ischaemic health strategy 25 employment untreated 20 disorders annual fast reaching automated revenues 325 brain 000 unknown brainomix market biomarkers easily clinical software version ltd euros computed direct financial biomarker budget hospital stroke validate receive scans hours projections model

Project "TISSUE" data sheet

The following table provides information about the project.

Coordinator	BRAINOMIX LIMITED Organization address address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD city: OXFORD postcode: OX2 7HN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2594-phc-12-2014.html
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2014
Duration (year-month-day)	from 2014-10-01 to 2015-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BRAINOMIX LIMITED BRAINOMIX LIMITED Organization address address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD city: OXFORD postcode: OX2 7HN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	50˙000.00

Map

Project objective

Stroke is a burden with far reaching socioeconomic impact. The only approved treatment in ischaemic stroke is intravenous thrombolysis, which is restricted to 4.5 hours after symptom onset and currently, only 20% of all stroke cases are eligible to receive it. An additional 25% remain untreated because they arrive at the hospital with unknown time of onset.

The objective of the “Tissue In Stroke Stratification Using e-ASPECTSTW” (TISSUE) proposal is to clinically validate the ASPECTS method and its automated version, the medical device software e-ASPECTSTW, as an imaging biomarker on Non-Contrast Computed Tomography (NCCT) brain scans for identifying ischaemic stroke patients with unknown time of onset who can benefit from thrombolysis.

e-ASPECTSTW addresses the growing worldwide market of 3,250,000 patients (275,000 patients in Europe) every year having a stroke with unknown time of onset. The annual global market size of e-ASPECTSTW is 325,000,000 Euros. Users of e-ASPECTSTW will be hospitals worldwide that provide acute stroke treatment. e-ASPECTSTW will be integrated in existing clinical pathways offering a standardised, fast, reliable and easily accessible assessment of NCCTs. This will increase the uptake of thrombolysis and provide significant economic benefits to hospitals and the health system. The commercial exploitation of the project results will enhance the growth of Brainomix Ltd leading to increased revenues, profits, employment and will position Brainomix as leaders in imaging biomarkers for neurological and cerebrovascular disorders.

The output of the feasibility study will be a full business plan, including an analysis of the European and global stroke market, an analysis of direct, indirect and potential competition; a detailed business model and pricing strategy as well as financial projections and a detailed design and budget of the prospective multi-centre clinical trial including the participating stroke units.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TISSUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TISSUE" are provided by the European Opendata Portal: CORDIS opendata.